期刊文献+

mAlb与NAG-ase联合检测对糖尿病肾病的早期诊断价值 被引量:1

The early diagnostic value of the combined detection of urine microamount albumin and N-β-D-glucosaminidase for diabetic nephropathy
下载PDF
导出
摘要 目的探讨联合检测尿微量白蛋白(mAlb)、N-乙酰-D-氨基葡萄糖苷酶(NAG-ase)水平对糖尿病肾病(DN)早期诊断的价值。方法采用免疫透射比浊法检测80例糖尿病患者的mAlb和NAG-ase的水平,并与对照组60例健康人进行比较,对结果进行统计分析。结果病程<5年的糖尿病患者的mAlb、NAG-ase与健康对照组比较差异无统计学意义(P>0.05);病程5~10年的患者与健康对照组比较,mAlb、NAG-ase差异有统计学意义(P<0.01);病程>10年的患者mAlb、NAG-ase明显高于健康对照组,差异有统计学意义(P<0.01)。随着年龄的增长,患者的mAlb、NAG-ase浓度也逐渐增加。结论 mAlb、NAG-ase联合检测对糖尿病肾病的早期诊断有非常重要的临床参考价值,可作为糖尿病肾病的早期诊断指标。 Objective To investigate the early diagnostic value of the combined detection of urine microamount albumin(mAlb) and N-β-D-glucosaminidase(NAG-ase) for diabetic nephropathy.Methods Urine mAlb and NAG-ase levels were examined with immunoturbidimetry in 80 di-abetics and 60 healthy subjects.The results were compared between patients and healthy controls and analyzed statistically.Results No difference inurine mAlb and NAG-ase between patients with diabetes less than 5 years and healthy control was found(P 0.05);however,significant differencesin mAlb and NAG-ase levels between patients with diabetes 5-10 years and healthy control were detected(P 0.05),and mAlb and NAG-aselevels in patients with diabetes more than 10 years were obviously higher than healthy control(P 0.05).In addition,urine mAlb and NAG-ase increased gradually with age.Conclusion The study suggests that the combined detection of MAlb and NAG-ase may act as indicator for the early diagnosis of diabetic nephropathy.
作者 田玉 李朋
出处 《临床和实验医学杂志》 2011年第15期1146-1147,共2页 Journal of Clinical and Experimental Medicine
关键词 糖尿病肾病早期 尿微量白蛋白 N-乙酰-D-氨基葡萄糖苷酶 Early diabetic nephropathy Urine microamount albumin N-β-D-glucosaminidase
  • 相关文献

参考文献8

二级参考文献52

共引文献106

同被引文献15

  • 1王瑞石,刘志红,尹茹,陈朝红,黎磊石.肾小管损伤标记物检测的临床意义及其影响因素[J].肾脏病与透析肾移植杂志,2005,14(2):110-116. 被引量:47
  • 2SYLVA SKALOVA. The diagnosis role of urinary N-acetyl-β-D- glucosaminidase (NAG) activity in the detection of renal tubular impairment [ J ]. Acta Medica, 2005,48 ( 2 ) : 75 - 80.
  • 3WELLWOOD JM, ELLIS BG, PRICE RG,et al. Urinary N-ace- tyl-β-D-glucosaminidase activities in patient with renal disease [J]. Br Med J,1975,3(5980) :408 -411.
  • 4魏有仁.尿液NAG酶测定方法及酶量排出的生理变动[J].中华医学检验杂志,1986,9(1):10-14.
  • 5LEONINE VAN MEER, MATTHIJS M, JACOBUS B,et al. Uri- nary Kidney biomarkers for early detection of nephrotoxicity in clinical drug development [ J]. Brit J Clin Pharm ,2013,77 ( 6 ) : 947 - 957.
  • 6WARING WS, MOONIE A. Earlier recognition of nephrotoxiticty using novel biomarkers of acute kidney injury [ J ]. Clln Toxicol, 2011,49:720 - 728.
  • 7LOGHMAN-ADHAM M, KIU WEBER CI, CIORCIARO C,et al. Detection and management of nephrotoxicity during drug develop- ment [ J ]. Expert Opin Drug Saf,2012,11 ( 4 ) :581 - 596.
  • 8DIETERLE F, SISTARE F, GOODSAID F, et al. Renal biomar- ker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium [ J ]. Nat Biotechnol, 2010, 28(5) : 455 -462.
  • 9FUCHS TC, HEWITT P. Biomarkers for drug-induced renal damage and nephrotoxicity-an ovmwiew for applied toxicology [J]. AapsJ, 2011, 13(4): 615-631.
  • 10徐旭,汤立达.FDA和EMEA批准7种肾损伤生物标志物正式使用[J].药物评价研究,2010,33(5):347-350. 被引量:18

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部